Rafael Holdings, Inc. (RFL) Posts FY26 Results; Q4 Loss Narrows
Czytanie zajmuje mniej niż 1 minutę
Rafael Holdings reported cash of $22.1M as of Jul 31, 2026. Q4 net loss was $9.2M ($0.18) vs $12.1M ($0.28) YoY; FY26 net loss was $29.6M ($0.58) vs $30.5M ($1.04). Company submitted an NDA for remibetadex in Oct 2026.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | Cash $22.1M at Jul 31, 2026 | Cash runway is tight for R&D; liquidity is key for going concern risk flagged in release. |
| 2 | Q4 net loss $9.2M vs $12.1M YoY | Loss narrowed mainly on lower G&A, a partial positive on burn. |
| 3 | Q4 G&A $2.4M vs $5.5M YoY | Cost controls reduced overhead; may improve runway. |
| 4 | Q4 R&D $7.5M flat YoY | Sustained R&D spend indicates continued development needs. |
| 5 | FY26 net loss $29.6M vs $30.5M | Slight improvement aided by one-time gains; core burn remains elevated. |
| 6 | NDA submitted for remibetadex Oct 2026 | Regulatory milestone; FDA acceptance/review status could be a major catalyst. |
Context by AI Analyst
This continues a cost-cutting trend while funding late-stage NPC therapy efforts after consolidating Cyclo Therapeutics. A larger catalyst hinges on FDA accepting and reviewing the NDA, potential priority review, and clarity on financing runway.
Based on the original press release from Rafael Holdings, Inc. distributed by GlobeNewswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.